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Abstract: Recent evidence suggests that the formation of soluble amyloid β (Aβ) aggregates with
high toxicity, such as oligomers and protofibrils, is a key event that causes Alzheimer’s disease
(AD). However, understanding the pathophysiological role of such soluble Aβ aggregates in the
brain in vivo could be difficult due to the lack of a clinically available method to detect, visualize,
and quantify soluble Aβ aggregates in the brain. We had synthesized a novel fluorinated curcumin
derivative with a fixed keto form, named as Shiga-Y51, which exhibited high selectivity to Aβ
oligomers in vitro. In this study, we investigated the in vivo detection of Aβ oligomers by fluorine-19
(19F) magnetic resonance imaging (MRI) using Shiga-Y51 in an APP/PS1 double transgenic mouse
model of AD. Significantly high levels of 19F signals were detected in the upper forebrain region of
APP/PS1 mice compared with wild-type mice. Moreover, the highest levels of Aβ oligomers were
detected in the upper forebrain region of APP/PS1 mice in enzyme-linked immunosorbent assay.
These findings suggested that 19F-MRI using Shiga-Y51 detected Aβ oligomers in the in vivo brain.
Therefore, 19F-MRI using Shiga-Y51 with a 7 T MR scanner could be a powerful tool for imaging Aβ
oligomers in the brain.
Keywords: magnetic resonance imaging; Alzheimer’s disease; mouse model; curcumin; keto-enol
tautomerism; imaging biomarker
1. Introduction
Amyloid β (Aβ), which is generally and ubiquitously expressed as peptides of pri-
marily 40 and 42 residues, forms insoluble fibrils and accumulates in extracellular deposits
known as senile plaques in the brain of patients with Alzheimer’s disease (AD) [1]. Genetic
evidence in familial AD cases strongly supports the amyloid cascade hypothesis; that is,
an imbalance between the production and clearance of Aβ is a very early, often initiating
factor in AD [2–4]. Moreover, recent evidence further suggests that the formation of sol-
uble Aβ aggregates with high toxicity, such as oligomers and protofibrils, is a key event
causing AD [5–10]. However, understanding the pathophysiological role of such soluble
Aβ aggregates in the brain in vivo could be difficult due to the lack of a clinically available
method to detect, visualize, and quantify soluble Aβ aggregates in the brain.
Recent advances in imaging techniques for in vivo detection of amyloid pathology in
the brain have attracted much attention [11–16]. Several recent studies have reported about
near-infrared (NIR) fluorescence imaging probes that selectively labeled Aβ oligomers in
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the in vivo brain of a mouse model of AD, including BoDipy-Oligomer (BD-Oligo) [17],
F-SLOH [18], CRANAD-102 [19], PTO-29 [20], and DCM-AN [21]. We have also reported
about a novel fluorinated curcumin derivative with high selectivity to Aβ oligomers, named
as Shiga-Y51 [22]. Curcumin is a yellow-orange pigment in turmeric, which exists in an
equilibrium state between the keto and enol tautomers (Figure 1), while Shiga-Y51 exists
only in the keto form due to the methyl and ethyl groups at the C4 position. In our previous
study, curcumin and the derivatives with keto-enol tautomerism were found to bind to Aβ
fibrils primarily in the enol form, but the keto form of curcumin derivative cannot bind to
Aβ fibrils [23]. Another study showed that curcumin and the derivatives with keto-enol
tautomerism can bind to Aβ oligomers [24]. The compounds that can bind to Aβ fibrils,
including thioflavin, Pittsburgh compound B (PiB), and the enol form of curcumin, have a
common flat and rather rigid structure with a ring system that is co-planar and possesses
π-electrons that are delocalized in the rings and move freely within them. We therefore
hypothesized that these molecules with flat and rather rigid structures bind to Aβ fibrils
easily but have some difficulty entering the hydrophobic core of Aβ oligomers because
of their rigidity. However, suitably sized hydrophobic molecules with flexible structures,
such as the keto form of curcumin derivative Shiga-Y51, could be incorporated within the
hydrophobic core of Aβ oligomers [22]. Our imaging mass spectrometry demonstrated the
accumulation of Shiga-Y51 in the brain regions where Aβ was detected in a mouse model
of AD after intravenous injection [22]. However, our previous study did not examine
whether Shiga-Y51 is a feasible imaging probe for Aβ oligomers.
Figure 1. Chemical structures of curcumin and Shiga-Y51. (a) Curcumin, a yellow-orange pigment in
turmeric, exists in an equilibrium between keto and enol tautomers. (b) Shiga-Y51 is a fluorinated
curcumin derivative with a fixed keto form by the methyl and ethyl groups at the C4 position.
In this study, we investigated the in vivo detection of Aβ oligomers using Shiga-Y51 by
fluorine-19 (19F) magnetic resonance (MR) imaging (MRI) in an APP/PS1 double transgenic
mouse model of AD. Our results demonstrated significantly high levels of 19F-MR signals
in the brain of APP/PS1 mice compared to that of wild-type mice. These findings suggest
that Shiga-Y51 could be a potential imaging probe for Aβ oligomers.
2. Results
2.1. Changes in the Levels of 19F-NMR Signals in the Mouse Head
Shiga-Y51 is a fluorinated curcumin derivative with methyl and ethyl groups at the C4
position, which fix it as the keto form in keto-enol tautomerism (Figure 1). APPswe/PS1dE9
double transgenic (APP/PS1) mice and wild-type mice were intravenously injected with
Shiga-Y51 at a dose of 200 mg/kg by continuous infusion over a 40 min period under
deep anesthesia with sodium pentobarbital (50 mg/kg, i.p.). The dose and injection rate of
0.5 mg/kg/min were determined based on the previous study using another curcumin
derivative Shiga-Y5 [23]. Our previous study using Shiga-Y5 indicated that the dose
of 200 mg/kg was tolerated and that the higher dose of 300 mg/kg was lethal (data not
shown). Furthermore, the highest level of the compound was detected when the compound
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was injected at 0.5 mg/kg/min via a tail vein in mice (data not shown). In this study, we
preliminarily injected Shiga-Y51 at the dose of 200 mg/kg and the rate of 0.5 mg/kg/min
in two mice to determine the tolerance dose in mice and found no apparent toxicity in the
two mice.
In this study, mice were subjected to in vivo MR measurement under deep anes-
thesia with intermittent infusions of sodium pentobarbital through a polyethylene tube
inserted intraperitoneally, because general inhalation anesthetic agents such as isoflurane,
sevoflurane, and desflurane contain fluorine atoms, causing background noise signals. We
monitored the respiratory rate and rectal temperature to determine the timing and addi-
tional dosage of sodium pentobarbital; however, infrequently, the mice woke up or died.
When the mice woke up during the MR measurement, the experiment was discontinued.
At 30 min after the injection, 19F nuclear MR (19F-NMR) was obtained for 10 min
using a 7 T MR scanner and repeated every 60 min (Figure 2). After the second 19F-
NMR measurement, 19F chemical shift imaging (19F-CSI) data for the 19F-MR images were
acquired for 50 min every 1 h (Figure 2).
Figure 2. Timeline of the present study. Shiga-Y51 (200 mg/kg, i.v.) was injected by a continuous infusion over 40 min
in APP/PS1 and wild-type mice under deep anesthesia. The first fluorine-19 nuclear magnetic resonance (19F-NMR)
measurement was performed 30 min after the injection and repeated every 60 min. Fluorine-19 chemical shift imaging
(19F-CSI) data for the fluorine-19 magnetic resonance (19F-MR) images were collected for 50 min every 1 h after the second
19F-NMR measurement.
The 19F-NMR spectra obtained every 60 min demonstrated intense 19F signals at
the first measurement and time-dependent declines in 19F signals in the wild-type mice
(Figure 3). In contrast, higher levels of 19F signals were detected in APP/PS1 mice at the
first 19F-NMR measurement and thereafter (Figure 3). However, no statistically significant
differences were observed in the levels of 19F-NMR signals between the wild-type and
APP/PS1 mice at any time points (Figure 3).
Figure 3. 19F-NMR spectra from the mouse head. (a–f) Representative 19F-NMR spectra from the mouse heads of wild-type
(WT) and APP/PS1 mice that were obtained every 60 min from 30 min after the injection. The spectra in (a) to (f) were
from the measurements 1 to 6 in Figure 2, respectively. (g) 19F-NMR spectra of Shiga-Y51 dissolved in DMSO. Chemical
shifts (ppm) were referenced to C6F6 at −163 ppm as an external standard. The FID signal was processed with 40 Hz line
broadening similarly to CSI data. The line width of 19F signal in the 19F-NMR of Shiga-Y51 dissolved in DMSO was 177 Hz,
whereas the 19F-NMR spectra from the mouse head showed the line width of 760 Hz. (h) The time course of changes in the
peak area was measured in WT (n = 4) and APP/PS1 mice (n = 3). Data are presented as mean ± standard error of mean (SEM).
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2.2. 19F-MRI
In this study, 19F-CSI data were collected without a slice-selective pulse. Therefore,
the 19F-MR images displayed whole signals covered by the coil sensitivity, including not
only in the brain but also in other tissues surrounding the brain, such as eyes and ears. This
experimental condition makes it difficult to analyze 19F signals in the olfactory bulb and
the cerebellum, as they are masked by the signals in the eyes and ears, where fluorinated
curcumin derivatives could be highly accumulated, because of high hydrophobicity. Hence,
we analyzed 19F signals separately in five regions (Figure 4). Region 1 includes the olfactory
bulbs and a part of the cerebral cortex wherein the signals in the eyes overlap. Regions 2
and 3 include the upper and lower parts of the brain, respectively. Region 4 includes the
cerebellum wherein the signals in the ears overlap, and region 5 includes the brain stem.
Figure 4. Accumulation of 19F signals in the brain of APP/PS1 mice. (a) Representative 19F-MR images in wild-type (WT)
and APP/PS1 mice that were obtained for 50 min in the first 19F-CSI measurement (at 100 min after the injection). A
lookup table (LUT) was used to display the 19F-MRI signal, and the white lines in each 19F-MR image indicate the outline
of the brain delineated based on the corresponding 1H-MR images. (b) The levels of 19F signals were measured in five
regions indicated in yellow color. Significantly high levels of 19F signals were detected in region 2 in APP/PS1 mice (n = 3)
compared with WT mice (n = 4). Data are presented as mean ± SEM. * p < 0.05 (unpaired t-test).
The wild-type (WT) mice displayed relatively high 19F signals in regions 1 and 4 in the
first 19F-CSI measurement obtained for 50 min from 100 min after injection with Shiga-Y51
(Figure 4). The APP/PS1 mice displayed intense 19F signals in region 2, in addition to
regions 1 and 4 (Figure 4). The 19F signals in 19F-MR images were then decreased in a
time-dependent manner in both WT and APP/PS1 mice (data not shown). The levels of 19F
signals in each region in the first 19F-CSI measurement exhibited a significant difference in
region 2 between the WT and APP/PS1 mice (p < 0.05; Figure 4). However, there were no
significant differences in the levels of 19F signals in other regions.
2.3. Levels of Aβ in the Brain of APP/PS1 Mice
Aβ accumulation was detected in the olfactory bulb, cerebral cortex, hippocampus,
and cerebellum of APP/PS1 mice (Figure 5). To validate the 19F-MRI results, we measured
the levels of soluble Aβ oligomers in the five regions using a commercially available
enzyme-linked immunosorbent assay (ELISA) kit with the same monoclonal antibody
specific to the N-terminal region of human Aβ (clone 82E1) for both capture and detection.
This ELISA kit can detect human Aβ molecules that bind to 82E1 antibody with two or more
epitopes. The measurement result is calculated in molarity as a relative value standardized
on the dimers of Aβ (1–16 residues). Our results revealed the highest accumulation of
soluble Aβ oligomers in region 2, followed by regions 4, 3, and 1. Region 5 showed very
low levels of soluble Aβ oligomers. Then, we measured the levels of soluble and insoluble
Aβ in the five regions. The highest levels of soluble Aβ40 were detected in region 2,
followed by regions 3, 4, 1, and 5 (Figure 5). Moreover, the pattern of the accumulation
levels of soluble Aβ42 in the five regions was similar to that of soluble Aβ oligomers, i.e.,
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the highest level of soluble Aβ42 was detected in region 2, followed by regions 4, 3, and
1. The levels of insoluble Aβ, which reflected the Aβ plaques consisting of insoluble Aβ
fibrils, were the highest in regions 1 and 2, followed by regions 3, 4, and 5 in insoluble
Aβ40, and in region 4, followed by regions 2, 1, 3, and 5 in insoluble Aβ42.
Figure 5. The levels of amyloid β (Aβ) in APP/PS1 mice. (a,b) Representative photographs showing
immunohistochemistry for Aβ in the sagittal (a) and coronal (b) sections of APP/PS1 mouse brain.
(c–h) The brains were cut into five pieces according to the dashed lines in (c), and the levels of Aβ
oligomers (d) in the soluble fraction and Aβ40 (e,g) and Aβ42 (f,h) in the soluble (e,f) and insoluble
(g,h) fractions were measured in each region. Data are presented as mean ± SEM. Scale bar: 1 mm.
3. Discussion
We explored whether Shiga-Y51 detected Aβ oligomers in the brain of APP/PS1 mice
using 19F-MRI with a 7 T MR scanner. Our results revealed the presence of significantly
high levels of 19F signals in the brain region, including the upper forebrain, of APP/PS1
mice, compared with the levels found in brains of WT mice. Moreover, the highest levels of
Aβ oligomers were detected in the upper forebrain of APP/PS1 mice. Our study findings
suggested that 19F-MRI using Shiga-Y51 detected Aβ oligomers in the in vivo brain of
APP/PS1 mice.
Aβ can easily polymerize with β-sheeted structures and form insoluble Aβ fibrils,
which accumulate in deposits known as senile plaques. Aβ can also form a different
type of aggregates, the so-called Aβ oligomers, which are small, soluble, and diffusible
enough to readily pass through the brain parenchyma to induce synaptic dysfunction and
memory impairment [24–27]. Our previous study demonstrated that curcumin derivatives
with keto-enol tautomerism bound to Aβ fibrils and oligomers [28,29]. In contrast, a
keto form of curcumin derivatives such as Shiga-Y51 exhibited high selectivity to Aβ
oligomers in vitro [22]. In this study, we used the APP/PS1 mouse model to verify the
in vivo detection of Aβ oligomers using Shiga-Y51 by 19F-MRI. This mouse model suffered
from the accumulation of both Aβ oligomers and fibrils in the brain regions where 19F
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signals were detected in 19F-MRI. Therefore, although we expected Shiga-Y51 to bind
selectively to Aβ oligomers in the in vivo brain as well, there could be the possibility of
its off-target binding to Aβ fibrils in the APP/PS1 mouse brain. However, for detecting
the signals in MRI, it is necessary to ensure that the free mobility of NMR nuclei is not
inhibited. When the free mobility of NMR nuclei is inhibited, the NMR signals would
be dramatically reduced due to shortening of T2 and broadening of the NMR signal [30].
Based on this knowledge, the 19F signals of Shiga-Y51 that possibly bind to Aβ fibrils
could not be detectable in the present study. In contrast, Shiga-Y51 bound to Aβ oligomers
would retain its mobility because of the free mobility of soluble Aβ oligomers. Hence, we
concluded that 19F-MRI using Shiga-Y51 in the present study would detect soluble Aβ
oligomers but not insoluble Aβ fibrils in the brain of APP/PS1 mice. In addition, highly
hydrophobic fluorine probes could be trapped by the lipid components of the brain such as
myelin, causing shortening of T2. Our preliminary study suggests that FID-type CSI data
acquisition using a surface coil was suitable for the detection of the relatively short T2 of
fluorine probes in the brain (data not shown), rather than echo signal of rapid acquisition
with relaxation enhancement (RARE) used by others [31]. Although further validation
and improvement of sensitivity are needed, MRI using molecular imaging probes would
have great potential in detecting the soluble oligomers of proteins that also form insoluble
fibrillar aggregates in the brain in neurogenerative diseases, such as Aβ, tau, α-synuclein,
and TDP-43.
This study showed a significant accumulation of 19F signals in brain region 2 in
APP/PS1 mice compared with WT mice. Region 2, consisting of the upper forebrain,
including the cerebral cortex and hippocampus, showed the highest level of Aβ oligomers
in ELISA measurements. Furthermore, no obvious background noise was detected in
region 2, and the position being closer to the coil than region 3 would be preferable for
highly sensitive detection. These results suggest that the levels of 19F signals could reflect
the level of Aβ oligomers in brain region 2 in APP/PS1 mice. In contrast, the levels of
19F signals in region 5 were not much different from those in regions 1 to 4 where at
least a 5-fold increase in levels of Aβ oligomers was detected in ELISA measurements.
Sensitivity and resolution would be improved to reflect the actual difference in the levels
of Aβ oligomers in each region.
In this study, there were no significant differences detected in 19F-NMR signals be-
tween the WT and APP/PS1 mice, although higher levels of 19F signals were detected
in APP/PS1 mice at all time points. In this study, we used a circular-type surface coil
measuring 1.6 cm in diameter and collected whole signals covered by the coil sensitivity
in the 19F-MR measurement. Consequently, 19F signals could be detected not only in the
brain but also in other tissues surrounding the brain, such as eyes and ears. As shown in
Figure 4, high levels of 19F signals were detected in the eyes and ears of WT mice, which
also overlapped the brain. Accordingly, the levels of 19F-NMR signals that consisted of the
signals not only in the brain but also in the eyes and ears would not reflect the levels of
Shiga-Y51 accumulated in the brain.
Several positron emission tomography tracers are clinically available, such as PiB,
flutemetamol, florbetaben, and florbetapir, which have been developed for imaging Aβ
fibrils in the brain [32]. However, there is a lack of a clinically available method for detecting
Aβ oligomers, although several attempts using NIR fluorescence imaging in mouse models
of AD have been successful, including BoDipy-Oligomer (BD-Oligo) [17], F-SLOH [18],
CRANAD-102 [19], PTO-29 [20], and DCM-AN [21]. Shiga-Y51 is a novel fluorinated
curcumin derivative with a fixed keto form, which is a completely different structure from
that of compounds targeting Aβ oligomers previously reported. Moreover, compared
with NIR fluorescence imaging, MRI has the advantage of the imaging depth. Hence, it is
probable that 19F-MRI using Shiga-Y51 would be a more feasible technique to detect Aβ
oligomers in the human brain.
19F-MRI would prove to be a highly sensitive, readily available, low-background, and
cost-effective approach once a suitable high-quality probe has been developed, including
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FSB [31], Shiga-Y5 [23], Shiga-X22 [33], and ShigaX35 [34], due to the following advantages:
the MR sensitivity of 19F is relatively high compared with various nuclei other than 1H (1H,
100%; 19F, 83%; 31P, 6.6%; 13C, 1.6%). No detectable fluorine atoms exist in biological tissues
(fluorine in bones and teeth are not appropriate for 19F MRI relaxation time), which could
result in low endogenous background noise. Furthermore, the 19F atom is a nonradioactive
isotope comprising 100% of naturally abundant fluorine. However, there were some
limitations in the application of 19F-MRI using Shiga-Y51 for imaging Aβ oligomers. First,
since strong unwanted signals were also detected even in the WT mouse brain, in which the
signals in the eyes and ears overlapped (the signals may not be a problem in human), it is
necessary to improve the accumulation of Shiga-Y51 in these tissues through modifications
to the probe structure. Second, the present 19F-MRI methodology requires a 7 T MR scanner;
however, the 7 T MR scanner is not a common imaging modality at the moment. Third, the
method of general anesthesia during long MR measurement should be improved. Although
we have no evidence of whether a significant dose of anesthesia would affect the results,
it may be possible that an additional dose of anesthesia between mice would affect the
results, because anesthesia depth could affect general parameters such as blood circulation,
respiration, and body temperature. Finally, it is important to improve the sensitivity for
safety reasons, because in this study, quite a high dose of probe (200 mg/kg) (which may
be near the value of LD50) was used for 19F-MRI. In an in vitro study, increasing the total
number of fluorine atoms in the probe enabled us to detect higher NMR signals. However,
the hydrophobicity of fluorine probes increases with the number of fluorine atoms because
of the hydrophobic property of fluorine atoms. This problem would cause low water
solubility and interaction with the lipid components of the brain, such as myelin [30,33].
Thus, increasing the number of fluorine atoms in the probe would not be an appropriate
way to develop a highly sensitive probe. In addition, improvement of water solubility of
Shiga-Y51 is needed to prepare the injection solution without a detergent.
In conclusion, understanding the accumulation of Aβ oligomers in the brain would
provide novel insights into the etiology, diagnosis, and treatment of AD. The results of this
study suggest that 19F-MRI using Shiga-Y51 with a 7 T MR scanner is a powerful tool for
imaging Aβ oligomers in the brain. Although further attempts are required for clinical
application, Shiga-Y51 could be a first-generation imaging probe targeting Aβ oligomers
in the brain.
4. Materials and Methods
4.1. Synthesis of Shiga-Y51
Shiga-Y51, namely, 1,7-bis(4′-hydroxy-3′-trifluoromethoxy)phenyl-4-ethyl-4-methyl-
1,6-heptadiene-3,5-dione, was synthesized as previously described [22].
4.2. Animals
All animal experiments were conducted according to the National Institutes of Health
Guide for the Care and Use of Laboratory Animals and were approved by the Animal Care
and Use Committee at the Shiga University of Medical Science (Number 2018-2-12).
APP/PS1 mice with a C57BL/6 background (Jackson Laboratory, Bar Harbor, ME,
USA), expressing a chimeric mouse/human amyloid precursor protein with the K594N
and M595L mutations linked to Swedish familial AD (Mo/HuAPP695swe) and human
PS1, carrying the exon 9 deletion associated with familial AD [35], were used in this study.
The mice were housed in standard laboratory cages at 23 ◦C with free access to water and
food in an SPF animal facility and maintained with a 12 h light/dark cycle with the lights
on from 8:00 a.m. to 20:00 p.m.
Female APP/PS1 mice (n = 4) aged 14.5–16.5 months and female WT mice (n = 3) aged
11.5–17 months were used for the MRI study. For ELISA measurements, female APP/PS1
mice aged 9 and 15 months (n = 3 each) were used.
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4.3. MRI
A 7 T horizontal-bore MR scanner (Unity Inova; Agilent Technologies, Santa Clara,
CA, USA) was used in this study. A custom-built circular-type surface coil (Takashima
Seisakusho, Tokyo, Japan) measuring 1.6 cm in diameter and tuned to both the 1H and 19F
frequencies (300 and 282 MHz, respectively) was used to collect the data. This RF coil had
no fluorine-containing materials, which cause instrument noise [36].
1H- and 19F-MR images were acquired as previously described [23,33,34]. Briefly, to
obtain 1H-MR images of the mouse brain, a gradient-echo sequence was used with 150 ms
repetition time (TR), 3 ms echo time, 60◦ flip angle, 1.5 mm slice thickness, 24 mm × 24 mm
field of view, and 128 × 128 resolution.
4.3.1. 19F-NMR Spectrum
A nonlocalized 19F-NMR spectrum was obtained from the whole head using a single
pulse sequence with 8192 data points, 40,000 Hz spectral width, 1 s TR, and 600 acquisitions
(for 10 min).
4.3.2. 19F-CSI
To obtain 19F-MR images, free induction decay data of 19F-CSI were collected with
a 40,000 Hz spectral width, 24 mm × 24 mm field of view in the sagittal plane, 1 s TR,
200 µs phase-encoding time, and 68 acquisitions for each central 44 phase-encoding step
of 8 × 8 steps. For the residual 20 phase-encoding steps in the periphery of k-space, zero
data were used. The total acquisition time for one data set was 50 min. As we did not use a
slice-selective pulse, whole signals covered by the coil sensitivity were acquired. The raw
data were processed by 3D-Fourier transformation with 40 Hz line broadening and zero
filling and finally converted into 32 × 32 spectral data sets.
4.3.3. Procedure of MR Measurement
Shiga-Y51 was dissolved at a concentration of 10 mg/mL in saline containing 10%
Cremophor EL. Under anesthesia using sodium pentobarbital (50 mg/kg, i.p.), mice were
intravenously injected at a dose of 200 mg/kg via the tail vein over a 40 min period by
continuous infusion at a rate of 0.5 mL/kg/min. Immediately after the injection, the mice,
whose heads were set on the RF coil, were placed in the MR scanner, and the 1H-MR
images were acquired. 19F-NMR were measured for 10 min at 30 min after the injection
and repeated every 60 min. 19F-CSI data for the 19F-MR images were collected for 50 min
every 1 h after the second 19F-NMR measurement (Figure 2).
General anesthesia was maintained with intermittent infusion of sodium pentobarbital
through a polyethylene tube inserted intraperitoneally. Any additional dosage of sodium
pentobarbital required for maintaining anesthesia was determined by monitoring the
respiratory rate. The animals were warmed with an air drier, and the rectal temperature
was monitored throughout the experiments.
4.4. Immunohistochemistry
Mice were sacrificed under deep anesthesia with sodium pentobarbital (200 mg/kg,
i.p.). The brain was quickly removed from each mouse. One brain hemisphere was post-
fixed in 4% paraformaldehyde for 24 h at 4 ◦C, and the other hemisphere was dissected
into five pieces as shown in Figure 5 and was stored at −80 ◦C. After 24 h post-fixation,
the brain hemisphere was immersed in 0.1 M phosphate buffer (pH 7.4) containing 15%
sucrose and 0.1% sodium azide for at least 2 days for cryoprotection and subsequently cut
into 20 µm sections in a cryostat.
Immunohistochemistry for detecting Aβ was performed as previously described [37,38].
Briefly, the free-floating brain sections in the sagittal plane were treated with 0.3% hydrogen
peroxide in 0.1 M phosphate-buffered saline (PBS) containing 0.3% Triton X-100 (PBS-T,
pH 7.4) to eliminate endogenous peroxidase activity. After several washes, the sections
were treated with 2% bovine serum albumin (BSA) in PBS-T for 30 min at room temperature
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to block nonspecific protein binding. The sections were then incubated with rabbit poly-
clonal antibodies against the N-terminal region of human Aβ (1:500; Immuno-Biological
Laboratories, Fujioka, Japan) in PBS-T containing 0.2% BSA for 24 h at 4 ◦C, followed by
incubation with biotinylated anti-rabbit IgG (1:1000; Vector Laboratories, Burlingame, CA,
USA) for 1 h at room temperature. The sections were then incubated with the avidin–biotin–
peroxidase complex (Vectastatin ABC Elite kit, 1:3000; Vector Laboratories) for 1 h at room
temperature. All sections were washed several times with PBS-T between each step, and la-
beling was detected using 3,3′-diaminobenzidine (DAB; Dojindo Laboratories, Kumamoto,
Japan), with nickel ammonium, which yielded a dark blue color. The sections were then
mounted on glass slides and coverslipped with Entellan (Merck, Darmstadt, Germany).
4.5. ELISA
Brain tissue extracts were prepared for ELISA measurements as previously described [37,38].
Briefly, frozen brain tissues were homogenized on ice in Tris-buffered saline (TBS; 25 mM
Tris-HCl, 150 mM NaCl, pH 7.4) (1-mL/150-mg wet weight) containing a protease inhibitor
cocktail (cOmplete Mini; Roche Diagnostics, Mannheim, Germany), sonicated, and then
centrifuged at 104,300× g for 60 min at 4 ◦C. The supernatant was collected as a TBS-soluble
fraction, and the remaining pellet was then resuspended in 70% formic acid in water, soni-
cated, and then centrifuged at 104,300× g for 60 min at 4 ◦C. The supernatant was recovered
and neutralized with a 20 fold dilution in 1 M Tris base. The protein concentration for each
sample was determined using a Bio-Rad protein assay kit (Bio-Rad Laboratories, Hercules,
CA, USA).
The levels of Aβ40 and Aβ42 were measured using a commercially available ELISA
kit (294-64701 and 290-62601, respectively; Wako Pure Chemicals, Osaka, Japan), according
to the manufacturer’s instructions. To detect Aβ oligomer species, an ELISA kit with the
same monoclonal antibody specific to the N-terminal region of human Aβ (clone 82E1)
for both capture and detection (27725; Immuno-Biological Laboratories, Fujioka, Japan)
was used. The absorbance in each well was measured at 450 nm using a microplate reader
(Infinite M200; Tecan, Männedorf, Switzerland).
4.6. Statistical Analysis
Data are presented as mean ± standard error of mean (SEM). The statistical signifi-
cance between wild-type control mice and APP/PS1 mice was analyzed by an unpaired
t-test using GraphPad Prism 7 (GraphPad Software, La Jolla, CA, USA).
5. Patents
Shiga University of Medical Science has submitted a Japanese patent application
(JP2020-033405) on Shiga-Y51, with D.Y., H.T. and I.T. named as the inventors.
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